|
|
|
|
|
|
Cannabis Science, Inc. CBIS
We are looking at CBIS today, after some pretty exciting news came over the wires on Tuesday. It isn't every day that a stock we trade makes a claim such as the one you will read below in the release. Marijuana killing cancer cells? If that doesn't spark your interest, you may want to check your pulse.
CBIS is a nice momentum play, having increased 100 percent in value yesterday, interest in the stock is at a high at the moment. Let's keep this on our scans and see how the story behind this PR plays out.
Cannabis Science Extracts Kill Cancer Cells In Cancer Patients Being Treated Through Its Licensed Distributor Rockbrook
DENVER, Feb 22, 2011 (BUSINESS WIRE) -- Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells. Cannabis Science, in conjunction with Rockbrook, its Colorado-licensed dispensary, consulted with a variety of cancer patients who were seeking to inform themselves of the current peer reviewed scientific literature, regarding the historical use of cannabis to treat "tumors". Unlike most conventional cancer treatments, cannabis has an outstanding safety profile, and patients in states with medical marijuana laws are able to make an informed decision to legally try various cannabis preparations to determine what is most effective for their particular condition.
Some of these scientifically informed patients have chosen to self-administer Cannabis Science extracts supplied by Rockbrook to treat their own cancers. Cannabis Science is delighted that patients are reporting dramatic improvements in their conditions, including basal cell carcinoma, non-small cell lung cancer accompanied by COPD (chronic obstructive pulmonary disease), ovarian cancer, and glioma.
Visit www.cannabisscience.com to view the successful results and images of the self-administered cancer treatments.
|
|
|
|
|
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. Bull in Advantage, LLC does on occasion sell shares in the open market without notice, and on occasion is compensated by a Third-Party for its above-referenced services with the company stock. Bull in Advantage, LLC reserves its right to buy and sell such securities at any time and without notice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. Bull in Advantage, LLC and its affiliates are not registered or liscenced investment advisors, nor broker dealers. Bull in Advantage, LLC advises that the investments in companies profiled are commonly considered to be high risk and use of the information provided is at the investor's sole risk.
|
|
|
|
